---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-195397"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:51:12.857753+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA approves Voranigo; Royalty Pharma pays $905M milestone, expects >$150M/yr royalties

## Summary
- FDA approved Voranigo (vorasidenib) for IDH1/2 mutant diffuse glioma on August 6, 2024.
- Royalty Pharma pays $905M to Agios upon approval under May 2024 royalty agreement.
- Royalty Pharma receives 15% royalty on U.S. net sales up to $1B, 12% above $1B.
- Peak annual sales projected >$1B; annual royalties >$150M through 2038.

## SEC filing metadata
- accession: 0001193125-24-195397
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524195397/0001193125-24-195397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524195397/d868175d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-195397
- JSON: https://secwatch.observer/filing/0001193125-24-195397.json
- Plain text: https://secwatch.observer/filing/0001193125-24-195397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.